Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Modified FOLFIRINOX clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 6 trials in our USA, UK, Israel, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Canada, Japan, Taiwan, Australia and South Korea registers that name Modified FOLFIRINOX as an intervention. Synced 10 Nov 2026
6Current trials
2Recruiting now
6Lead sponsors
16Country registers
At a glance

Modified FOLFIRINOX is named as an intervention in 6 current clinical trials in our USA, UK, Israel, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Canada, Japan, Taiwan, Australia and South Korea registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is EXACT Therapeutics AS (1). The most-studied condition is Locally Advanced Pancreatic Adenocarcinoma.

Patient leaflets for Modified FOLFIRINOX

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting233%
  • Not yet open117%
  • Active, closed350%

Trials by phase

  • Phase 2233%
  • Phase 1/2233%
  • Phase 1117%
  • Phase 3117%
01

Clinical trials of Modified FOLFIRINOX

6 trials
StudyPhaseStatusLead sponsorRegisters
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
NCT06850623 · Locally Advanced Pancreatic Adenocarcinoma
Phase 2 Recruiting EXACT Therapeutics AS UK, USA, Israel
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
NCT05257993 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma
Phase 1/2 Recruiting Onconic Therapeutics Inc South Korea
Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC
NCT07833241 · ClinicalTrials.gov ↗ · Borderline Resectable Pancreatic Cancer, High-Risk Resectable Pancreatic Cancer
Phase 2 Not yet open Shanghai Zhongshan Hospital China
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
NCT03899636 · ClinicalTrials.gov ↗ · Stage III Pancreatic Cancer
Phase 3 Active, closed Angiodynamics, Inc USA
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
NCT05585320 · Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous)
Phase 1/2 Active, closed Immuneering Corporation USA
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
NCT06360354 · Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Phase 1 Active, closed Amgen UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Canada, Japan, Taiwan, Australia, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Modified FOLFIRINOX

10 conditions
Locally Advanced Pancreatic Adenocarcinoma1Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers1Advanced Solid Tumor1Pancreatic Adenocarcinoma1Malignant Melanoma (Cutaneous)1Non-small Cell Lung Cancer (NSCLC)1Stage III Pancreatic Cancer1Borderline Resectable Pancreatic Cancer1High-Risk Resectable Pancreatic Cancer1Pancreatic Ductal Adenocarcinoma1
05

Related compounds

06

Questions about Modified FOLFIRINOX trials

How many clinical trials are testing Modified FOLFIRINOX?

6 current trials in our USA, UK, Israel, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Canada, Japan, Taiwan, Australia and South Korea registers name Modified FOLFIRINOX as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Modified FOLFIRINOX trials recruiting patients?

Yes. 2 of the 6 trials are recruiting: 1 with sites in USA, 1 with sites in UK, 1 with sites in Israel and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Modified FOLFIRINOX clinical trials?

EXACT Therapeutics AS (1), Amgen (1), Immuneering Corporation (1) and Angiodynamics, Inc (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Modified FOLFIRINOX works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Modified FOLFIRINOX works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Modified FOLFIRINOX (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.